Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIFT: Lonafarnib, Ritonavir, and Lambda Interferon for Chronic Delta Hepatitis
NCT03600714Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lonafarnib, peginterferon lambda-1a in hepatitis D (HDV), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Aug 2018; status: completed.
02
Drugs
lonafarnibpeginterferon lambda-1a
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT03600714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600714.